Amgen on Friday closed its $27.8 billion acquisition of Horizon Therapeutics, about one month after securing clearance from U.S. antitrust regulators who had challenged the …
Dive Brief: Gene therapy developer Orchard Therapeutics has agreed to be bought by Japan’s Kyowa Kirin in a deal that highlights the challenges of commercializing …
AbbVie has acquired a small biotechnology company and its experimental treatment for Parkinson’s disease, adding to a recent string of deals that have expanded the …
#DD2023 #ELRIG #drugdiscovery23 The most important drug discovery event of the year is just around the corner! ELRIG (The European Laboratory Research & Innovation Group) …
Dive Brief: Shares in Structure Therapeutics jumped Friday after the San Francisco-based biotechnology company released results from a small study of an experimental weight loss …
Liver drug developer Intercept Pharmaceuticals has agreed to be acquired by Italian company Alfasigma for about $800 million, the companies announced Tuesday, ending one of …
New vaccines for respiratory syncytial virus offer a significant opportunity this fall for protection against a pervasive public health threat. Their arrival in the U.S., …
A group of advisers to the Food and Drug Administration on Wednesday determined that a controversial therapy for ALS does not have enough evidence to …
A combination of cancer drugs from Seagen and Merck & Co. has shown early success in a large clinical trial, results that help confirm the …
A Food and Drug Administration advisory committee voted unanimously on Thursday afternoon to reject an appeal for Intarcia Therapeutics’ Type 2 diabetes drug-device combination treatment, …
“Molecular glues” — so named for their ability to forcibly pull together two proteins that wouldn’t otherwise interact with each other — have come a …
Dive Brief: Novartis has terminated a global deal with BeiGene, retaining full rights back on the cancer immunotherapy tislelizumab, the China-based biotech said Tuesday. Also …
The biotech is telling investors it expects to launch as many as 15 new products, from which it is forecasting billions of dollars in annual …
The company’s lead drug, izokibep, missed its goal in a late-stage trial, though Acelyrin said it sees some hope in the results. Dive Brief: Acelyrin …
Led by former Nimbus executive Rosana Kapeller, the startup has now raised nearly $200 million in its pursuit of new autoimmune disease and cancer therapies. …
Backed by Johnson & Johnson’s venture arm, among others, Arialys plans to take medicine it acquired from Astellas Pharma into clinical testing next year. A …
Group aims to improve access to scientific programmes and grow ELRIG community. Cambridge, UK, 14 September 2023: The European Laboratory Research & Innovation Group (ELRIG) UK …
In a multi-year research alliance, the companies aim to combine Seagen’s antibody technology with compounds that can degrade cancer-driving proteins. Dive Brief: Seagen is committing …
The companies will work together to pair Shape’s adeno-associated virus technology with Otsuka’s genetic payloads. Japan’s Otsuka Pharmaceutical will work with Seattle startup Shape Therapeutics …
The collaboration will use Verge Genomics’ platform, which has developed a novel candidate for ALS using data from human tissue. Dive Brief: Verge Genomics, a …
